American Research Journal of Cardiovascular Diseases

 Morbidities following antihyperlipidemic treatmentsuch as muscular and hepatic disorders have been reported in the literature. According to new guidelines high intensity antihyperlipidemic therapy is a class I recommendation for patients with clinical atherosclerotic cardiovascular disease or low density lipoprotein cholesterol ≥ 190 milligram per deciliter, although existing data regarding initiation or continuation of statin therapy in symptomatic heart failure patients (New York Heart Association Class II-IV) are equivocal. I sought to evaluate morbidities associated with unproven treatment in heart failure patients because it may decrease the number of problems in these patients which is very valuable. Based upon the experience of seeing and treating patients with heart failure, I have observed signs and symptoms of skin dryness and pruritus in these patients which was related to their antihyperlipidemic treatment. This relationship was supported by the disappearance of these signs and symptoms after discontinuing their antihyperlipidemic drug and increasing fat in their diet. Improvement was seen by the next visit within one to two months of the intervention. I also observed that some of these patients had been treated for their symptoms with treatments for dermatitis and without response to topical treatment. Evaluation of clinicalsign and symptomsof skin dryness and pruritus related to extreme antihyperlipidemic treatment is important, because it decreases the number of morbiditiesin heart failure patients and prevents inappropriate andpotentiallydeleterious therapies.